Wall Street brokerages expect Puma Biotechnology Inc (NYSE:PBYI) to report $3.60 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Puma Biotechnology’s earnings. The lowest sales estimate is $2.50 million and the highest is $4.90 million. The business is expected to report its next earnings results on Wednesday, November 8th.

On average, analysts expect that Puma Biotechnology will report full year sales of $3.60 million for the current fiscal year, with estimates ranging from $19.60 million to $22.77 million. For the next year, analysts anticipate that the firm will post sales of $247.39 million per share, with estimates ranging from $209.10 million to $296.56 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Puma Biotechnology.

Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.78).

Several equities research analysts recently weighed in on PBYI shares. Credit Suisse Group boosted their target price on Puma Biotechnology from $118.00 to $136.00 and gave the stock an “outperform” rating in a research note on Monday, September 11th. J P Morgan Chase & Co restated a “buy” rating on shares of Puma Biotechnology in a research note on Tuesday, August 1st. Stifel Nicolaus boosted their target price on Puma Biotechnology from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, October 2nd. BidaskClub upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 3rd. Finally, Zacks Investment Research cut Puma Biotechnology from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Puma Biotechnology has an average rating of “Buy” and a consensus target price of $124.89.

ILLEGAL ACTIVITY WARNING: “Brokerages Expect Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $3.60 Million” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/17/brokerages-expect-puma-biotechnology-inc-pbyi-will-post-quarterly-sales-of-3-60-million.html.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 1,998 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $94.48, for a total value of $188,771.04. Following the completion of the sale, the senior vice president now owns 27,246 shares in the company, valued at $2,574,202.08. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Alan H. Auerbach sold 13,175 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $94.73, for a total value of $1,248,067.75. Following the completion of the sale, the insider now owns 4,170,623 shares of the company’s stock, valued at approximately $395,083,116.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 45,173 shares of company stock valued at $4,738,189. 22.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Paulson & CO. Inc. lifted its stake in Puma Biotechnology by 75.3% in the second quarter. Paulson & CO. Inc. now owns 27,500 shares of the biopharmaceutical company’s stock valued at $2,404,000 after buying an additional 11,810 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Puma Biotechnology by 5.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 140 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Puma Biotechnology by 2.0% in the second quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock valued at $1,950,000 after purchasing an additional 437 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Puma Biotechnology in the second quarter valued at approximately $146,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Puma Biotechnology in the second quarter valued at approximately $162,302,000. Institutional investors own 80.98% of the company’s stock.

Puma Biotechnology (NYSE PBYI) opened at 124.15 on Tuesday. The stock’s market capitalization is $4.62 billion. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $127.02. The company has a 50 day moving average of $108.65 and a 200 day moving average of $77.41.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.